Pharma Pioneer

Kura Oncology Begins Trial of KO-2806 and Cabozantinib for Kidney Cancer

19 May 2024
2 min read

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, has commenced the first patient dosing with KO-2806, a farnesyl transferase inhibitor (FTI), combined with tyrosine kinase inhibitor (TKI) cabozantinib in Phase 1 of the FIT-001 trial targeting clear cell renal cell carcinoma (ccRCC). This development represents a critical step for KO-2806, happening alongside ongoing dose escalation as a standalone treatment.

The Phase 1 FIT-001 trial is investigating KO-2806's safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor effectiveness, both as a monotherapy and in combination with other targeted treatments. Future plans include combining KO-2806 with adagrasib for treating KRASG12C-mutant non-small cell lung cancer (NSCLC).

Kura's Chief Medical Officer, Stephen Dale, M.D., emphasized that this trial cements their position in developing FTIs and demonstrates the compound's potential when paired with TKIs like cabozantinib to combat resistance mechanisms and enhance antitumor responses. The company aims to broaden KO-2806's use as a combination therapy to optimize antitumor activities and counteract treatment resistance.

Additional details about the FIT-001 study and KO-2806's preclinical data, including its efficacy with various targeted therapies, were discussed at the 2023 AACR-NCI-EORTC conference. Kura's clinical program includes other candidates, such as ziftomenib for acute myeloid leukemia (AML) and tipifarnib for head and neck squamous cell carcinoma, under various clinical trials.

Kura Oncology remains focused on developing precision cancer therapies. The company faces risks such as clinical trial uncertainties, regulatory challenges, and financial dependencies. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Syncromune® Showcases Early SYNC-T™ SV-102 Trial Data at AACR 2024
Pharma Pioneer
2 min read
Syncromune® Showcases Early SYNC-T™ SV-102 Trial Data at AACR 2024
19 May 2024
Syncromune®, Inc., will showcase groundbreaking data from their Phase 1 clinical trials of SYNC-T, a pioneering in situ platform therapy tailored for solid tumor cancers.
Read →
Sionna Secures $182M for Cystic Fibrosis Treatment Development to Rival Vertex
Pharma Pioneer
2 min read
Sionna Secures $182M for Cystic Fibrosis Treatment Development to Rival Vertex
19 May 2024
Sionna Therapeutics, based in Massachusetts, has successfully concluded a Series C funding round, raising $182 million.
Read →
Promising Interim Phase 1 Results for ALG.APV-527 in Solid Tumors with 5T4 Antigen
Pharma Pioneer
2 min read
Promising Interim Phase 1 Results for ALG.APV-527 in Solid Tumors with 5T4 Antigen
19 May 2024
Encouraging interim results have emerged from the Phase 1 clinical trial of ALG.APV-527, a drug developed by Alligator Bioscience AB and Aptevo Therapeutics.
Read →
Phase 1 Trial Indicates CAR T Cell Therapy's Efficacy Against Aggressive Brain Tumors
Pharma Pioneer
3 min read
Phase 1 Trial Indicates CAR T Cell Therapy's Efficacy Against Aggressive Brain Tumors
19 May 2024
The therapy involves the use of genetically modified T cells that target a specific protein, interleukin-13 receptor alpha 2 (IL13Rα2), which is overexpressed in glioblastomas.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.